Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03765502 · ClinicalTrials.gov registry record · Phase 1
A Study Comparing User Experience of Different Delivery Devices for Glucagon
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 99
- Enrollment target
NCT03765502: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT03765502 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 99 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03765502, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 99 participants
- Enrollment target
Study Summary
The purpose of the study is to learn more about different devices for delivering glucagon during simulations of severe hypoglycemic (low blood sugar) emergencies. The study will be carried out using medical manikins to simulate real life scenarios. No drug will be administered to humans. Part A will last approximately 17 days for Trained Users and Participants with Diabetes (PWD). Part B will last approximately nine (9) days for Untrained Users. Each part will be separated by approximately 7 days.
Primary Outcome
Percentage of trained users who found both devices and performed a successful administration of both rescue devices for both simulations.
Interventions
- DEVICE Nasal Glucagon Device (NG)
- DEVICE GEK
- DRUG IM Glucagon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2018-11-19 |
| Est. Completion | 2019-01-03 |
| Phase | Phase 1 |
What the finished NCT03765502 record still lists
NCT03765502 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% higher).
The record links to 0 conditions, and to 3 interventions - of which Nasal Glucagon Device (NG) is the first listed.
NCT03765502 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03765502 about?
NCT03765502 is a clinical study titled "A Study Comparing User Experience of Different Delivery Devices for Glucagon". The purpose of the study is to learn more about different devices for delivering glucagon during simulations of severe hypoglycemic (low blood sugar) emergencies. The study will be carried out using medical manikins to simulate real life scenarios. No drug will be administered to humans. Part A will...
What is the current status of trial NCT03765502?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 99 participants. The study started on 2018-11-19. Estimated completion is 2019-01-03.
What interventions are being tested in trial NCT03765502?
The interventions under investigation include: Nasal Glucagon Device (NG) (DEVICE), GEK (DEVICE), IM Glucagon (DRUG).
Who is sponsoring clinical trial NCT03765502?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03765502's enrollment target sits among peer trials
99 590th of 2000 higher than 1,409 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI